tbuckley/cabot-search huggingface dataset:
Abstract A72: Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells.
Authors: Carrie D. House, Christina M. Annunziata
Journal: Clinical Cancer Research (2016)

Abstract Ovarian cancer is the most lethal gynecological malignancy in the United States with high morbidity and mortality due to recurrence and chemoresistance. Our data suggest tumor-initiating cells (TICs) play an important role in disease biology. We previously showed that a subset of ovarian cancer cells depends on NF-kappaB signaling, and that expression of NF-kappaB proteins is associated with poor survival. To investigate this pathway in TICs, we designed a novel method to enrich for TICs from cell lines and patient samples by culturing non-adherent, floating cells in stem cell conditions. Preliminary data show these cells have higher stem cell marker expression, are chemoresistant, and are more tumorigenic in nude mice compared to their adherent counterparts. Given that NF-kappaB expression correlates with a poor outcome in ovarian cancer, and NF-kappaB activity supports drug resistance and tumorigenicity, we hypothesize that NF-kappaB supports a TIC program responsible for ovarian cancer relapse. Preliminary data show TIC-enriched culture conditions increased NF-kappaB expression and activity in TICs and stimulation of NF-kappaB signaling enhanced chemoresistance and stem cell marker expression. Current studies focus on dissecting the role of individual NF-kappaB proteins in TICs using inducible shRNAs to measure changes in spheroid formation, chemoresistance, tumorigenesis, and disease relapse following chemotherapy in a xenograft model. Future studies will measure system level changes induced by these shRNAs, and identify a gene signature specific to NF-kappaB in ovarian TICs. Clarifying the nuances of NF-kappaB signaling in TICs will increase our understanding of ovarian cancer recurrence and may lead to improved therapeutic strategies. Citation Format: Carrie D. House, Christina M. Annunziata. Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A72.
Combined hepatocellular‐cholangiocarcinoma in a patient with Abernethy malformation and tetralogy of Fallot: A case report
Authors: Sofie Happaerts, Amélie Foucault, Jean Sébastien Billiard, Bich Nguyen, Franck Vandenbroucke‐Menu
Journal: Hepatology (2016)

Abernethy malformation is a rare congenital anomaly of the portal vein where the portal blood bypasses the liver. We report the first case of a patient with Abernethy malformation and tetralogy of Fallot associated with nodular regenerative hyperplasia and focal nodular hyperplasia (FNH), which finally evolved to a giant hepatocellular-cholangiocarcinoma (HCC-CC) of the liver, successfully resected. (Hepatology 2016;64:1800-1802).
Book: International Consensus on the Diabetic Foot
Authors: Paul Newrick
Journal: BMJ (2000)

International Working Group on the Diabetic Foot


Available from M Wijnandts, Department of Internal Medicine, Academic Hospital Maastricht, Netherlands, fl35 




ISBN 90 9012716 x

———————

Rating: ★★★

Why is the diabetic foot so important that we need consensus, and international consensus at that? The reason is partly statistical and partly personal. Around the world at least 120 million people have diabetes, and up to 10% will develop foot ulceration at some time. About 9% of NHS funds are spent dealing with diabetes; nearly half of this is for hospitalisation for complications, particularly of the diabetic foot. Throughout the developed world similar healthcare costs are incurred, but in the developing nations the scarcity of care means that most of the costs are social.

Such is the public health picture, but there is a more personal and equally disturbing side. Patients often live with chronic discharging ulcers, pain, and progressive deformity. Repeated outpatient attendances, dressing changes, antibiotics, and surgical procedures are often the norm. Enforced rest and time lost from work add to the misery.

This is the background to the formation of the International Working Group on the Diabetic Foot. Opinion leaders in the subject have produced this paperback publication, which purports to be a consensus on the diabetic foot, with particular emphasis on screening and prevention. Consensus is only collective opinion, but my colleagues and I had no difficulty in agreeing with the vast majority of the material, including those areas for which the evidence base is currently rather thin.

Ulceration of the diabetic foot is no accident. It starts with a mix of sensorimotor and autonomic neuropathy, usually with a degree of vascular insufficiency. Unfortunately, inadequate advice from healthcare professionals and maladaptive patient behaviour can hasten the pathological process. Reduction of new and recurrent ulceration and amputations is an important organisational challenge for us all, at whatever level in the system we work. Molecular biology may be the answer to diabetic complications in the future but not today. For now, simple screening of at risk feet and straightforward treatments are cost effective.

International Consensus on the Diabetic Foot says little that is new, but its mix of textbook and care manual is authoritative and easy to read. There is clear advice on the necessary clinical examinations and programmes, backed up by colour photographs and learning points. The forthcoming national service framework on diabetes will stimulate interest in systematic preventive care, so this book is well timed.
PWE-052 Low uptake of cervical screening in immunosuppressed patients with inflammatory bowel disease at a district general hospital
Authors: K Wade, H Johnson, H Dewhurst, S Weaver, S McLaughlin
Journal: Gut (2015)

<h3>Introduction</h3> ECCO guidelines strongly recommend regular cervical screening for women with inflammatory bowel disease (IBD), especially if treated with immunomodulators. We wanted to investigate if our immunosuppressed female IBD patients were being screened in accordance with the NHS Cervical Screening Programme (CSP) and identify if they were at increased risk of cytological abnormalities. <h3>Method</h3> We searched our database for patients commenced on azathioprine, mercaptopurine, methotrexate, infliximab or adalimumab from June 2005 to October 2013. We excluded patients who were on these drugs for less than one year, were not of cervical screening age (25–64) or had had a hysterectomy. Information provided from general practitioners, local cytology department and Open Exeter (CSP database) were used to identify women participating in CSP and if they showed any abnormalities. <h3>Results</h3> 153 patients met the criteria to participate in the CSP. 115 (75%) were up-to-date compared to a national participation rate of 78.3%. 25 (16%) had participated in the CSP but were not up-to-date at the time of report. 9 (6%) had not participated in the CSP and 4 (3%) actively declined participation. Date from the 2013 National CSP demonstrates that 5.3% of those screened displayed low grade abnormalities and 1.2% had high grade abnormalities. Of our 153 patients 13 (8.5%) had cytological abnormalities. 5 (3%) patients had abnormalities before immunosuppressive therapy with 1 (0.7%) patient showing high grade abnormality (moderate dyskaryosis with CIN1 confirmed) which subsequently remained negative whilst on immunosuppression. Our results identified 7 (4.6%) patients with low grade abnormal cytology results after commencing immunomodulators (3; borderline nuclear changes in squamous cells, 2; mild dyskaryosis, 2; low grade dyskaryosis and high risk HPV detected). Only 1 (0.7%) patient had high grade dyskaryosis during immunosuppression but their follow up cytology was negative. <h3>Conclusion</h3> IBD patients are at increased risk of cytology abnormalities which is concerning since our CSP participation is below the national average. However data from our unit suggests that commencing immunosuppression therapy did not increase that risk any further. This data underlines that IBD specialists need to educate and encourage patients to participate in the CSP programme. <h3>Disclosure of interest</h3> K. Wade Conflict with: Abbvie sponsorship to attend ECCO, H. Johnson: None Declared, H. Dewhurst: None Declared, S. Weaver Conflict with: been on advisory board for MSD and Abbvie but not for past 12 months, S. McLaughlin Conflict with: Abbvie sponsorship to attend DDW, Abbvie Advisory board, Ferring sponsorship to attend ECCO.
Pressure mounts to ban smoking in public places
Authors: Z. Kmietowicz
Journal: BMJ (2003)

The chief medical officer has urged the government to make smoking in public places and at work illegal, to protect people from the dangers of secondhand smoke.

In his annual report Professor Liam Donaldson said that banning smoking at work would have the same impact on rates of quitting as would doubling the price of a packet of cigarettes. It …
High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission
Authors: PF Coccia, SE Strandjord, PI Warkentin, NK Cheung, EM Gordon, LJ Novak, DC Shina, RH Herzig
Journal: Blood (1988)
Fraud and abuse of government medical benefit programs by psychiatrists
Authors: G Geis, P Jesilow, H Pontell, M J O'Brien
Journal: American Journal of Psychiatry (1985)

Government rosters of physicians suspended from the Medicare and Medicaid programs because of fraud and abuse indicate that psychiatrists form a disproportionately large segment of the total. Of the factors contributing to this situation, the most notable is that because psychiatrists charge for time rather than for services, they are more readily apprehended if they violate the rules. The authors speculate on whether in fact psychiatrists break the law more than physicians in other-specialties or whether the statistics are purely artifactual.
Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis
Authors: Silvia M Rojas, María Díez-Campelo, Elisa Luño, Teresa Bernal, Monica Cabrero, Carme Pedro, Marisa Calabuig, Benet Nomdedeu, Teresa Cedena, Beatriz Arrizabalaga, Marta Garcia, Carlos Cerveró, Rosa Collado, Gemma Azaceta, MarÃa Teresa Ardanaz, Juan A Muñoz, Blanca Xicoy, María José Requena, Joan Bargay, María Jesús Arilla, Luz Amigo, Brayan Merchan, Adriana Simiele, Salut Brunet, Bernardo Gonzalez, Fernando Ramos, Francesc Solé, Del CaÃ‘izo Consuelo
Journal: Blood (2013)
Childbirth
Authors: Janet M. Torpy
Journal: JAMA (2005)

Childbirth Atypical pregnancy lasts about 40 weeks (9 months) from a woman' s last menstrual period.During this time, the fetus develops inside the mother' s uterus (womb).As the pregnancy approaches term, the uterus changes and begins to have contractions in the process of labor leading to childbirth.Obstetricians are doctors trained in the health care of pregnant women, including methods of delivery.Nurse midwives are registered nurses who specialize in the care of pregnant women, including labor and nonoperative methods of delivery.The May 4, 2005, issue of JAMA includes an article about episiotomy (an incision to widen the opening of the vagina) during the childbirth process.
URINARY NOREPINEPHRINE EXCRETION IN ELDERLY HYPERTENSIVE PATIENTS DURING ADMINISTRATION OF FUSARIC ACID
Authors: Fujio Terasawa, Lie Hon Ying, Takaomi Suzuki, Hiroyoshi Hidaka
Journal: Circulation (1976)

The urinary norepinephrine excretion during fusaric acid calcium salt administration was examined in 5 elderly hypertensive patients by double blind cross-over method. The average daily excretion of the last 5 days during fusaric acid calcium salt or placebo administration of 5 weeks' duration was compared in each patient. In 4 patients except for one, the average daily urinary excretion of norephinephrine during fusaric acid calcium salt administration showed an increase, being highly significant (p<0.01) statistically, when compared with that during placebo administration, the latter being essentially unchanged. In the one patient, however, the average daily urinary excretion of norepinephrine was significantly higher during placebo administration than that during fusaric acid calcium salt administration. The relationship between the changes in the average daily urinary excretion of norepinephrine and those in blood pressures seemed to be not consistent. The mechanism which brought about an increased norepinephrine excretion in the urine of the hypertensive patients is not obscure at present.
DDW Reports 2003 Orlando: Reflux Disease and Barrett’s Esophagus
Authors: T Rösch
Journal: Endoscopy (2003)

Gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE) continue to be major topics in the field of clinical research. More data are accumulating on the endoscopic diagnosis of subtle abnormalities, to allow better classification of patients into endoscopy-positive and endoscopy-negative (NERD, non-erosive reflux disease) groups. The situation regarding endoscopic antireflux techniques has not become much clearer. Some abstracts were presented to both societies.
Diagnosing Lead Poisoning
Authors: M Abramowicz
Journal: New England Journal of Medicine (1999)

Alternative Medicine -The Case of Herbal RemediesTo the Editor: With respect to the editorial on alternative medicine by you and Angell (Sept.17 issue), 1 if we look outside our own borders at the policies of other developed countries, we find a more rational approach to herbal medicine.In Germany, physicians are required to have some training in herbal medicine.Considerable research on herbal medicine -including double-blind, placebocontrolled trials -is ongoing. 2 Physicians recommend and patients use herbal medicines extensively.Manufacturers are required to meet standards of purity and pharmaceutical activity.Commission E, which has had oversight of herbal medicines and has determined their safety and efficacy, has published 387 monographs (recently translated into English by the American Botanical Council). 2Several other European countries 2 also have policies and procedures that allow rational oversight of herbal medicines.In the United States, herbs are used either as dietary supplements, with minimal standards of safety and efficacy, or as drugs, which require expensive and cumbersome testing procedures.I would argue for a more middle-of-the-road approach that acknowledges the long history of use of many herbal medicines, examines data from many sources including other countries, insists on strict production standards, and requires absolute safety and a classification of efficacy that may vary from "unproved" for some conditions to "demonstrated" for others.The use of the translated Commission E monographs would be very helpful for patients and physicians.
Abstract 5815: Effects of Atorvastatin on F-18 Fluorodeoxyglucose Accumulation on Positron Emission Tomography in Atherosclerotic Plaques: The EARDROP Study
Authors: Hideki Ishii, Takanobu Toriyama, Toru Aoyama, Hiroshi Takahashi, Miho Tanaka, Masami Nishio, Tsuneo Tamaki, Motohiro Miyagi, Tetsuya Amano, Tadayuki Uetani, Tatsuaki Matsubara, Toyoaki Murohara
Journal: Circulation (2008)

In atherosclerosis, plaque vulnerability is strongly related to rupture, and vulnerable plaques contain numerous inflammatory cells, particularly macrophages, suggesting that inflammation is closely associated with plaque instability. Recently, it has been suggested that F-18 fluorodeoxyglucose (FDG) on positron emission tomography (PET) is a useful technique for detection of local inflamed atherosclerotic lesions. We therefore examined the effects of atorvastatin on F-18-FDG accumulations in atherosclerotic plaques at common carotid and ascending aorta. A total of 20 patients with dyslipidemia but not treated with medication were enrolled and imaged using F-18-FDG -PET and CT for baseline measurement. They were randomized to receive 20-mg or 5-mg atorvastatin after imaging and F-18-FDG -PET and CT were checked again 6 months later. Changes in the standard uptake value (SUV) of F-18-FDG-accumulation rate (plaque/integral plasma) between baseline and follow-up were evaluated. After atorvastatin treatment, serum C-reactive protein (CRP) levels, low-density lipoprotein (LDL) cholesterol levels and malondialdehyde-modified LDL (MDA-LDL) cholesterol levels were significantly reduced (CRP levels: from 1277±704 mg/dl to 609±314 mg/dl, p &lt; 0.0001, LDL cholesterol levels: from 154±29 mg/dl to 98±29 mg/dl, p &lt; 0.0001, MDA-LDL cholesterol levels: 178.4±70.8 IU/l to 125.4±49.7 IU/l, p &lt; 0.0001, respectively). The maximum SUV significantly decreased at follow-up (common carotid arteries: from 1.36 ±0.13 g/dl to 1.28 ±0.22 g/dl, p = 0.047, ascending aorta: from 1.63 ±0.20 g/dl to 1.53 ±0.16 g/dl, p = 0.032, respectively). Notably, the decrease in the SUV was well correlated with reduction of serum CRP levels (common carotid arteries: r = 0.52, ascending aorta: r = 0.47, respectively), LDL cholesterol levels (common carotid arteries: r = 0.46, ascending aorta: r = 0.43, respectively) and MDA-LDL cholesterol levels (common carotid arteries: r = 0.47, ascending aorta: r = 0.43, respectively). Six-month atorvastatin treatment had anti-inflammatory effects and decreased SUV detected by F-18-FDG -PET, which might represent regression of aortic vulnerability.
Abstract P6-13-18: Triple-negative kinase profile guides in the selection of the multi-kinase inhibitor EC70124 as an active antitumor agent
Authors: J Perez-Peña, G Serrano-Heras, V Corrales-Sánchez, C Nieto-Jimenez, MJ Gascón-Escribano, JC Montero, F Moris, M Martin, A Pandiella, A Ocana
Journal: Cancer Research (2016)

Abstract Introduction: Identification of the kinase profile of triple negative tumors can guide in the selection of active multi-kinase inhibitors. We describe the preclinical selection of a novel kinase inhibitor based on the kinase profile identified in human samples. Methods: phosphokinase profiles of human samples were performed using two kinase arrays: human phospho-RTK array kit (# ARY001, R&amp;D Systems, Abingdon, UK) and the PathScan RTK Signaling Antibody Array Kit (# 7982,Cell Signaling Technology). Based on the kinase profile, inhibitors against activated proteins were evaluated in a panel of triple negative cell lines. Proliferation and growth was measured by MTT uptake. Evaluations of apoptosis and cell cycle were performed by flow cytometry using Annexin V and propidium iodide, respectively. Gene-set enrichment analyses were performed to identify relevant functions mediated by the drug and the identified genes were confirmed by RT-PCR. The in vivo antitumoral effect was evaluated using xenografted animals. Results: Several kinases were constitutive activated in human tumors, including AKT and pS6, among others . Pharmacological screening identified PI3K/mTOR inhibitors as the most active agents. The novel multi-kinase inhibitor, EC-70124 showed clear antitumor activity. Doses of EC70124 in the nanoMolar ranged reduced proliferation and cell growth in a panel of triple negative cell lines including HS578T, BT549, MDA-MB231 and HCC3153. Treatment with EC70124 inhibited the PI3K/mTOR pathway and induced DNA damage. Gene set enrichment analyses showed different cellular functions induced by the compound. EC70124 showed activity in xenografted animals. Pharmacodynamic analyses supported the inhibition of the PI3K/mTOR pathway in vivo. Conclusion: the kinase profile of human triple negative tumors identified major activated pathways including the PI3K/mTOR route. The novel kinase inhibitor EC70124 inhibited the PI3K/mTOR pathway showing clear antitumor activity. Evaluation of the kinase profile followed by functional studies is an attractive approach to rationally select active antitumoral agents. Citation Format: Perez-Peña J, Serrano-Heras G, Corrales-Sánchez V, Nieto-Jimenez C, Gascón-Escribano MJ, Montero JC, Moris F, Martin M, Pandiella A, Ocana A. Triple-negative kinase profile guides in the selection of the multi-kinase inhibitor EC70124 as an active antitumor agent. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-18.
New Transplantable Hamster Tumor: A Squamous Cell Carcinoma of the Skin
Authors: I N Chernozemski
Journal: JNCI Journal of the National Cancer Institute (1967)

A papillomatous squamous cell carcinoma of hamster skin was transplanted and is.now in its 67th generation. After a latency of 10–13 days, it took, became necrotic early, and ulcerated. An evolution was detected histologically: The basal epithelium and basel membrane disappeared graduallYi the pattern changed to that of cell nests and diffuse types, some with many cavities, predominantly vessels. Thetumorcells were spinous only, with average cell and nucleus diameters of about 25 and 11 µ, respectively, and with perfectly visible tonofibrils and intercellular bridges. Keratin was evident in layers, cell groups, and large dyskeratotic cells with keratohyalin granules. Succinic-dehydrogenase and sulfhydryl activities were observed around the nuclei of the living, nonkeratinized cells. Stromal fibers and cells were scarce, but vessels were numerous.
The Sialylation Pathway and Coronary Artery Disease
Authors: Anne Tybjærg-Hansen
Journal: New England Journal of Medicine (2016)

Plasma levels of non–high-density (non-HDL) cholesterol are causally linked to the risk of coronary artery disease. Non-HDL cholesterol levels are a better predictor of cardiovascular risk than levels of low-density lipoprotein (LDL) cholesterol alone, because non-HDL cholesterol comprises all known cholesterol-containing lipoproteins that can cause atherosclerosis, including LDL, very-low-density lipoprotein, intermediate-density lipoprotein, chylomicrons and their remnants, and lipoprotein(a).Nioi et al. now report in the Journal important genetic evidence suggesting a causal association between ASGR1, a gene encoding the major subunit of the asialoglycoprotein receptor, and cardiovascular disease.1 Nioi and colleagues sequenced the genomes of 2636 Icelanders and identified variants . . .
Proto-oncogene structure and breast cancer prognosis.
Authors: M V Viola
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.7.993 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3474359 Proto-oncogene structure and breast cancer prognosis. M V ViolaxM V ViolaSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.7.993 First Page PDF © 1987 by American Society of Clinical Oncology
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Authors: Marianna Sabatino, Jinhui Hu, Michele Sommariva, Sanjivan Gautam, Vicki Fellowes, James D. Hocker, Sean Dougherty, Haiying Qin, Christopher A. Klebanoff, Terry J. Fry, Ronald E. Gress, James N. Kochenderfer, David F. Stroncek, Yun Ji, Luca Gattinoni
Journal: Blood (2016)
Case 13-1965
Authors: Stanley M. Wyman, Austin L. Vickery
Journal: New England Journal of Medicine (1965)

Presentation of CaseA forty-eight-year-old woman entered the hospital because of an abnormal "shadow" on an x-ray film of the chest.She had been well until three months previously, when a routine x-ray film of the chest was reported to show "a shadow" on the right side. A tuberculin skin test was negative on two occasions. She stated that she experienced occasional "twinges" of pain in the anterior portion of the right side of the chest during the three months before entry.The patient had smoked 4 or 5 cigarettes daily during the seven years before admission and had gained . . .